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Background: Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection
(CDI), but inconsistent effect rates and uncertain evidence levels have warranted caution. To clarify, we
aimed to establish the evidence of FMT for recurrent CDI, updated across different delivery methods, treat-
ment regimens, and in comparison with standard antibiotics.
Methods: In this updated systematic review and meta-analysis, we searched PubMed, Scopus, Embase, Web
of Science, Clinical Key, and Svemed+ for FMT literature published in English until November 11, 2019. We
included observational and clinical trials with or without antibiotic comparators and excluded studies with
below 8 weeks follow-up and fewer than 15 patients. The primary outcome was clinical outcome by week 8.
We comprehensively extracted patient and procedural data. In a random-effects meta-analysis, we estimated
the clinical effect for repeat or single FMT, different delivery methods, and versus antibiotics. We rated the
evidence according to the Cochrane and GRADE methods. The PROSPERO preregistration number is
CRD42020158112.
Findings: Of 1816 studies assessed, 45 studies were included. The overall clinical effect week 8 following
repeat FMT (24 studies, 1855 patients) was 91% (95% CI: 8994%, I2=53%) and 84% (8088%, I2=86%) follow-
ing single FMT (43 studies, 2937 patients). Delivery by lower gastrointestinal endoscopy was superior to all
other delivery methods, and repeat FMT significantly increased the treatment effect week 8 (P<0¢001). Com-
pared with vancomycin, the number needed to treat (NNT) for repeat FMT was 1¢5 (1¢31¢9, P<0¢001) and
2.9 (1¢537¢1, P=0¢03) for single FMT. Repeat FMT had high quality of evidence.
Interpretation: High-quality evidence supports FMT is effective for recurrent CDI, but its effect varies with the
delivery method and the number of administrations. The superior NNT for FMT compared with antibiotics
suggests that patients may benefit from advancing FMT to all instances of recurrent CDI.
Funding: Innovation Fund Denmark (j.no. 8056-00006B).
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Faecal microbiota transplantation (FMT) is an effective treatment
for recurrent Clostridioides difficile infection (CDI) [13]. CDI is a lead-
ing cause of antibiotic-associated diarrhoea [4], and 2232%experience prolonged or recurrent infections unresponsive to stan-
dard antibiotics [5,6]. Recurrent CDI is associated with a high mortal-
ity [7], and preventing the infection poses a substantial therapeutic
challenge with limited treatment options. During the last decade,
FMT has emerged as a viable treatment for recurrent CDI. With effect
rates of up to 94% in clinical trials [13], FMT is now recommended
by scientific societies and National Health agencies for patients with
2 or more recurrences of CDI [810].
Previous systematic reviews [1117] have confirmed the high
clinical effect of FMT for recurrent CDI and indicated that the treat-
ment effect may depend on the method of delivery and treatment
regimens [15,16]. Still, no clear clinical evidence exists for the cumu-
lative effect of FMT following single or repeated treatment regimens,
Research in context
Evidence before this study
Faecal microbiota transplantation (FMT) is recommended for
patients with two or more recurrent Clostridioides difficile infec-
tions (CDI), but uncertain evidence levels limit the advancing of
FMT. Prior to the present study, we searched PubMed, Scopus,
Embase, Web of Science, Clinical Key, and Svemed+ for litera-
ture published until Jun 26, 2019 on the clinical use of FMT for
recurrent CDI, using the search terms Clostridiodes/Clostridium
difficile, faecal/fecal microbiota transplantation/ transplant,
installation, and bacteriotherapy. Several previous systematic
reviews confirmed an overall 9293% clinical cure rate for
recurrent CDI following FMT, but they did not compare FMT
with the current standard of care and had limited power to
evaluate the magnitude of effect for delivery methods and
treatment regimens combined.
Added value of this study
This updated systematic review and meta-analysis establishes a
high quality of evidence for repeat FMT administered for recur-
rent CDI with an overall 91% effect rate at week 8 and a number
needed to treat (NNT) of 1.5 compared with standard antibiot-
ics. The study provides effect estimates specific for each deliv-
ery method and treatment regimen, confirming that the effect
of FMT varies accordingly. This will help clinicians inform their
patients of anticipated treatment effects and more effectively
plan treatment courses for recurrent CDI.
Implications of all the available evidence
A large body of high-quality evidence now underpins the con-
clusion that FMT is effective for managing recurrent CDI. The
low NNT for FMT suggests that FMT should be translated from
an experimental treatment reserved for the few to a standard
of care offered to all patients with recurrent CDI.
ARTICLE IN PRESS
JID: ECLINM [m5G;November 26, 2020;12:54]
2 S.M.D. Baunwall et al. / EClinicalMedicine 00 (2020) 100642and the quality of evidence for FMT compared with standard
antibiotics has been rated as moderate in previous systematic
reviews and guidelines due to inconsistencies [10,13]. These
inconsistencies have resulted in caution and questioned the posi-
tion of FMT in the CDI treatment algorithm until the evidence for
FMT has been evaluated in more detail [18]. Now, further to these
earlier systematic reviews, more evidence has accumulated, and
new methods of delivery have emerged; as such, an update of
the evidence with the latest data is pivotal to guide clinical deci-
sions and improve the future recommendations for FMT in man-
aging patients with recurrent CDI.
The aims of this systematic review and meta-analysis were to
establish the evidence for using FMT in recurrent CDI, to provide
updated effect estimates specific to different delivery methods and
treatment regimens, and to compare the effect of FMT with that of
standard antibiotics.
2. Methods
In this systematic review and meta-analysis, we adhered to the
Preferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines (Supplementary File 1) and the instructions
described in the Cochrane Handbook [19,20]. The review protocol
was preregistered and is accessible at http://www.crd.york.ac.uk/
PROSPERO (CRD42020158112).Please cite this article as: S.M.D. Baunwall et al., Faecal microbiota trans
systematic review and meta-analysis, EClinicalMedicine (2020), https://dOverall, the review addressed three principal questions:
1 What is the overall effect of FMT in treating recurrent CDI?
2 Does the effect of FMT vary according to delivery method or
treatment regimen?
3 What is the effect of FMT compared with standard antibiotics in
patients with recurrent CDI?
2.1. Data sources and searches
We searched the medical databases PubMed, Scopus, Embase,
Web of Science, Clinical Key, and Svemed+ for all available literature
published until November 11, 2019. The search string was con-
structed to include the different terminologies used to describe the
procedure (Supplementary Table 1).
2.2. Study selection
Inclusion criteria were: published randomised clinical trials
(RCT) and observational cohort studies with more than 15
patients. We included English language studies using FMT to treat
recurrent CDI, with or without an antibiotic comparator, in an
adult population (18+ years) with no prior FMT treatments and a
follow-up period of at least 8 weeks. We defined FMT as the
transfer of processed faeces from healthy, allogenic donors. We
excluded autologous FMT and microbial treatments sourced from
cultured microbial consortiums. As a cut-off value to restrict the
study population to recurrent CDI only, studies were excluded if
they included 10% adolescents or 10% patients with refractory,
index CDI. Studies that failed to report clinical outcomes or had
selective reporting were excluded. For studies reporting outcomes
from the same population at different time points, we included
the most recent if the superseding study was of equal quality.
Subsidiary studies conducting additional sub-analyses were omit-
ted in favour of the original study with more details.
All references were imported and managed in Covidence (Cov-
idence systematic review software, Veritas Health Innovation,
Melbourne, Australia.). Two independent reviewers (SMDB and
MM) screened and fully read potential articles for eligibility, and
one reviewer (CH) arbitrated discrepancies. Two reviewers (BHM
and JRM) challenged the robustness of the final search strategy
by checking for potential missing studies and inconsistencies.
2.3. Outcome assessment
The primary outcome was effect with sustained resolution week 8
following single or repeated courses of FMT, or antibiotics. We evalu-
ated effect according to the guideline definitions for resolution of C.
difficile-associated diarrhoea (CDAD) as either i) clinical resolution of
diarrhoea, or ii) persistent diarrhoea with a negative CD test [8,10].
For FMT, the outcomes were grouped overall and according to deliv-
ery method.
We evaluated the FMT treatment effect according to treatment
regimens in two categories for a) single FMT and b) repeat FMT.
For single FMT, we defined treatment effect as the number of
patients with effect following one FMT. We considered FMT per-
formed in a pre-planned series as the same single FMT reflecting
an increase in dose. For repeat FMT, we defined treatment effect
as the total, cumulative number of patients with effect following
one or more FMT, i.e., including both initial non-responders to
the first FMT who later achieved treatment effect from a subse-
quent FMT as well as the patients only requiring one FMT to
achieve treatment effect. Consequently, repeat FMT reflects the
total FMT treatment effect if FMT is repeatedly performed as
needed until resolution of symptoms. Follow-up time was from
the last FMT.plantation for recurrent Clostridioides difficile infection: An updated
oi.org/10.1016/j.eclinm.2020.100642
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on the method of application and retention times in: i) lower gastro-
intestinal (GI) endoscopy (colonoscopy, enteroscopy, sigmoideo-
scopy), ii) upper GI administration (nasojejunal/gastric tube,
gastroscopy, gastrostomy tube), iii) capsules, and iv) enema (rectal
installation and rectal catheter).
2.4. Data extraction
Two reviewers (SMDB and MM) independently extracted the data
to an Excel spreadsheet with predefined record forms. One reviewer
(MKE) validated all data in the final dataset. In case of unexplainable
study discrepancies, the authors were contacted. To provide the most
conservative estimates, data were extracted according to a strict
intention to treat principle: For studies reporting outcomes only on
patients with complete follow-up, drop-outs were registered as fail-
ures, and for studies summarising an overall treatment effect for
both FMT and antibiotics, patients who did not achieve effect from
the FMT but from a subsequent antibiotics course were also counted
as failures. Studies that did not adhere to the CDAD definition for
effect was as conservative measures based on the reporting of clinical
effect. Death during failure up counted as failures.
For studies with >8 weeks follow-up, we extrapolated long-term,
follow-up outcomes for sustained responses to week 8 outcomes, if
the week 8 outcome was not reported separately. To account for
reporting bias in studies with >8 weeks follow-up, we counted all
CDI relapses in the >8-week period as treatment failures. We
extracted week 1 data for single FMT when reported.
For delivery method specific estimates, we extracted data both
separately and combined overall for each study if a study used more
than one FMT delivery method. Patients who received repeat FMT
with a change in delivery method were categorised according to their
first delivery method.
To account for methodological, procedural, and patient-related
aspects potentially influencing the clinical effect, we comprehen-
sively extracted data for these parameters. From each study, donor
type, processing method, and dose was extracted. Because a previous
systematic reviews indicated a clinical effect of administrating 50 g
of crude faeces or more [15,17], we included this as a binary variable
for each study. Patient-related parameters included age, sex, previous
number of CDI recurrences, comorbidity, and refractory CDI. Refrac-
tory CDI, defined as sustained symptoms despite sufficient standard
antibiotics treatment, was assessed according to the reporting in
each study.
2.5. Risk of bias assessment and quality of evidence
Two reviewers (SMDB and MM) evaluated the study quality for
each study. Cohort studies were evaluated with the Newcastle-
Ottawa quality assessment Scale (NOS) [21] and randomised clinical
trials with the Cochrane Risk of Bias 2 (RoB2) tool [22]. NOS scores
range from 0 (lowest) to 9 (highest) and require reviewers to incor-
porate predefined quality determinants for comparability. For FMT,
we defined reporting processing method and dose as critical for com-
parability. The RoB2 tool categorises bias risk in three categories:
low, moderate, and high. To yield comparable estimates, we consid-
ered a NOS score of 89 as low, 57 as moderate, and 4 as high risk
of bias.
The GRADE methodology [23] was used to determine the quality
of evidence for each of the three study questions and derive summary
of findings tables.
2.6. Data analysis
For all statistical analyses, we used R version 3.6.1 with the
“meta”, “metafor”, and “dmetar” extension packages [24,25]. WePlease cite this article as: S.M.D. Baunwall et al., Faecal microbiota trans
systematic review and meta-analysis, EClinicalMedicine (2020), https://dapplied a random effects model with a DerSimonianLaird tau2 esti-
mator and Z-based statistics for all meta-analyses, and when applica-
ble, results were summarised in forest plots. P-values <0¢05 were
considered statistically significant, and all data were presented with
95% confidence intervals (CI).
The proportional FMT effect data were pooled as weighted aver-
ages overall and across the four categories for delivery method and
according to single or repeat FMT. Only studies reporting stratified
effect rates according to delivery method were included in the
grouped analysis for delivery method, and only studies performing
repeat FMT with a report of the pairwise effect rates were included in
the cumulative effect analysis for single versus repeat FMT.
We transformed all effect data with the FreemanTukey Double
Arcsine transformation to stabilise the variance and correct for the
skewness introduced by high effect studies whose weight of the
upper intervals is otherwise not accounted for. For all estimates, we
calculated the prediction intervals indicating the expected FMT effect
in future studies. The subgroup analyses of delivery methods were
evaluated with Wald-type statistics and referenced with lower GI
delivery. Repeat and single FMT was compared using a one-propor-
tion Z statistics assuming a no difference null-hypothesis between
the transformed repeat minus single FMT effect estimates. For the
GRADE summary table, we used the absolute difference in weighted
between single and repeat FMT. To detect if extreme study outliers
influenced the estimates too heavily, we performed outlier and
leave-one-out analyses for each analysis. We prespecified extreme
outliers as studies whose confidence intervals did not overlap with
the pooled estimate’s confidence interval.
Only randomised clinical trials with an antibiotic comparator
were included in the analysis of FMT versus antibiotics. Antibiotics
was compared with both single and repeat FMT. The effects of FMT
compared with antibiotics were expressed as risk difference and rela-
tive risk with a derived number need to treat (NNT) with confidence
intervals. We calculated the NNT from the inverse absolute risk dif-
ference (risk antibiotics minus risk FMT).
Heterogeneity, arising from other than statistical probability, was
quantified with I2 statistics and significance tested with a chi-squared
method (P-values >0.05 was considered as significant heterogene-
ity). According to the Cochrane Handbook [20], we considered I2-val-
ues between 040% as minimal, 3060% as moderate, 5090% as
substantial, and 75100% as considerable heterogeneity. Significant
heterogeneity was examined using multimodal inference to con-
struct, unbiased meta-regressions explaining influential study mod-
erators while accounting for different moderator combinations.
Publication bias was evaluated by visual inspections of funnel
plots and tested for asymmetry with Egger’s test when 5 studies or
more were included. Duval and Tweedie’s trim-and-fill procedure
[26] was applied to determine direction of potential publication bias.
2.7. Role of the funding source
The study was funded by the Innovation Fund Denmark (j.no.
8056-00006B). The funding source was independent of the study and
had no role in study design, data collection, data analysis, data inter-
pretation, or writing of the report. The corresponding author had
access to all the data in the study and had final responsibility for the
decision to submit for publication.
3. Results
The search strategy identified 1816 unique studies, of which 332
were read in full following the initial screening of titles and abstracts.
Of these, we included 45 studies [13,2768] that comprised 9 rand-
omised clinical trials and 36 cohort studies. Fig. 1 displays the out-
come of the full search strategy, and Supplementary File 2 provides
exact reasons for dismissal for each excluded study read in full.plantation for recurrent Clostridioides difficile infection: An updated
oi.org/10.1016/j.eclinm.2020.100642
Fig. 1. PRISMA flowchart of included and excluded studies.
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overall summary of findings with GRADE quality of evidence are pre-
sented in Tables 2 and 3.
Across all studies, the mean patient age was 65¢8 years with 66%
being women experiencing on average 3¢7 CDI episodes. Pre-treat-
ment with antibiotics (metronidazole, vancomycin, or fidaxomicin)
prior to FMT was described in all but four studies (9%) and lasted
from four days up to long-term, tapered regimens. One study per-
formed FMT without antibiotic pre-treatment on a subset of their
cohort [61]. Risk of bias assessments for each study are provided in
Supplementary Fig. 1 and Supplementary File 3. Supplementary
Tables 2 and 3 describes processing methods, donor types, and
patient characteristics in each of the included studies.
Clinical effect week 8 overall was 91% (8994%, I2=53%) for repeat
FMT based on 24 studies with 1855 patients and 84% (95% CI
8088%, I2=86%) for single FMT based on 43 studies with 2937
patients. Two studies [44,67] for repeat FMT and seven studies
[30,34,36,45,46,48,50] for single FMT were extreme study outliers.
Omitting the studies, either separately or as a group, markedly
reduced study heterogeneity (single FMT I2=50%, repeat FMT I2=24%)
but did not affect the overall effect rates.Please cite this article as: S.M.D. Baunwall et al., Faecal microbiota trans
systematic review and meta-analysis, EClinicalMedicine (2020), https://dClinical effect week 1 following single FMT was reported in nine
studies with 384 patients. The pooled, overall effect week 1 was 94%
(8699%, I2=76%) compared with 88% (8094%, I2=67%) week 8
(P=0¢069). No studies were extreme outliers. Subgroup analyses were
not possible because few studies provided week 1 outcome data.
Effect estimates specific to the delivery method were reported in 22
studies with 1513 patients for repeat FMT and 41 studies with 2754
patients for single FMT (Table 2). Delivery by lower GI endoscopy was
superior to delivery by upper administration (repeat FMT P=0¢001, sin-
gle FMT P<0¢001), capsules (repeat FMT P=0¢051, single FMT P=0¢001),
and enema (repeat FMT P=0¢009, single FMT P<0¢001) (Table 2). We
graded the quality of evidence for one deliverymethod (lower GI endos-
copy) being superior to the other delivery methods as low for repeat
FMT and as moderate for single FMT (Table 2). The low rating for repeat
FMT was due to a low gain in absolute effect between the delivery
methods. The prediction intervals for the estimated effect of FMT in
future studies are presented in Table 4, and Supplementary Figs. 2 and 3
present the forest plots for the stratified, meta-analytic effect estimates.
For repeat and single FMT compared (Fig. 2), pairwise effect rates
were reported in 23 studies with 1357 patients (Table 2). We found a
high quality of evidence supporting that repeated use of FMTplantation for recurrent Clostridioides difficile infection: An updated
oi.org/10.1016/j.eclinm.2020.100642
Table 1
Main characteristics of the 45 included studies (9 randomised clinical trials and 36 cohort studies).
FMT Effect Quality assessment
Author Country Study type FMT category Patient
No.
Week 1
Single
Week 8
Single
Week 8
Repeat
Follow-up
(weeks)a
Age
(mean)
Female
(%)
CDAD No. CDI
(mean)
NOS RoB2
Garborg et al., 2010 [27] Norway Cohort Upper administration 40 ¢¢ 29 (72%) 33 (82%) 11¢4 75¢0 53¢0 + NA Low risk ¢¢
Kelly, 2012 [28] USA Cohort Lower GI endoscopy 26 ¢¢ 24 (92%) ¢¢ 8¢0 59¢0 92¢3 + NA Moderate risk ¢¢
Brandt et al., 2012 [29] USA Cohort Lower GI endoscopy 77 ¢¢ 70 (91%) 72 (94%) 73¢6 65¢0 73¢0  NA High risk ¢¢
Mattila et al., 2012 [30] Finland Cohort Lower GI endoscopy 70 ¢¢ 66 (94%) 66 (94%) 46¢0 73¢0 60¢0 + 3¢5 Low risk ¢¢
Rubin et al., 2013 [31] USA Cohort Upper administration 75 ¢¢ 59 (79%) ¢¢ 8¢6 63¢0 65¢3  NA Moderate risk ¢¢
van Nood et al., 2013 [1] Netherlands RCT Upper administration 16 ¢¢ 13 (81%) 15 (94%) 10¢0 73¢0 50¢0 + 3¢0 ¢¢ Low risk
Youngster et al., 2014 [32] USA Cohort Capsule 20 14 (70%) 14 (70%) 18 (90%) 8¢0 64¢5 45¢0 + 3¢0 Low risk ¢¢
Youngster et al., 2014 [33] USA RCT Overall 20 14 (70%) 14 (70%) 18 (90%) 8¢0 54¢5 55¢0 + 4¢5 ¢¢ Low risk
USA RCT Lower GI endoscopy 10 8 (80%) 8 (80%) 10 (100%) 8¢0 50¢4 60¢0 + 4¢0 ¢¢ Low risk
USA RCT Upper administration 10 6 (60%) 6 (60%) 8 (80%) 8¢0 58¢6 50¢0 + 5¢0 ¢¢ Low risk
Dutta et al., 2014 [34] USA Cohort Lower GI endoscopy 27 ¢¢ 27 (100%) ¢¢ 89¢3 64¢5 81¢5  5¢0 Moderate risk ¢¢
Khan et al., 2014 [35] USA Cohort Lower GI endoscopy 20 ¢¢ 18 (90%) 20 (100%) 12¢0 66¢3 65¢0 + 5¢0 Moderate risk ¢¢
Lee et al., 2014 [36] Canada Cohort Enema 94 ¢¢ 45 (48%) 86 (91%) 26¢0 71¢8 56¢4  2¢1 Moderate risk ¢¢
Cammarota et al., 2015 [2] Italy RCT Lower GI endoscopy 20 ¢¢ 13 (65%) 18 (90%) 10¢0 71¢0 60¢0 + 3¢0 ¢¢ Low risk
Costello et al., 2015 [37],b Australia Cohort Lower GI endoscopy 16 15 (94%) 14 (88%) 16 (100%) 13¢0 69¢0 NA + 3¢0 High risk ¢¢
Hirsch et al., 2015 [38] USA Cohort Capsule 19 ¢¢ 13 (68%) 17 (89%) 13¢0 61¢0 68¢4 + 4¢0 Moderate risk ¢¢
Satokari et al., 2015 [39],c Finland Cohort Lower GI endoscopy 38 ¢¢ 36 (95%) 37 (97%) 12¢0 57¢8 65¢8 + 4¢0 Low risk ¢¢
Youngster et al., 2016 [40] USA Cohort Capsule 180 ¢¢ 147 (82%) 164 (91%) 8¢0 64¢0 NA + NA Moderate risk ¢¢
Agrawal et al., 2016 [41] USA, Canada,
Australia
Cohort Overall 146 ¢¢ 128 (88%) 133 (91%) 53¢3 78¢6 68¢5 + NA Low risk ¢¢
Girotra et al., 2016 [42] USA Cohort Lower GI endoscopy 29 ¢¢ 27 (93%) ¢¢ 12¢0 80¢1 79¢3 + NA Moderate risk ¢¢
Kelly et al., 2016 [43],d USA RCT Lower GI endoscopy 22 ¢¢ 20 (91%) ¢¢ 8¢0 48¢0 82¢0  4¢0 Moderate risk ¢¢
Khoruts et al., 2016 [44] USA Cohort Lower GI endoscopy 272 ¢¢ 243 (89%) 262 (96%) 8¢0 57¢2 69¢5 + 5¢0 Low risk ¢¢
Lee et al., 2016 [45] Canada RCT Enema 219 ¢¢ 113 (52%) 193 (88%) 13¢0 72¢7 66¢7 + 2¢6 ¢¢ Low risk
Orenstein et al., 2016 [46] USA Cohort Enema 34 ¢¢ 16 (47%) 27 (79%) 8¢0 66¢8 67¢6  NA Moderate risk ¢¢
Waye et al., 2016 [47] Canada Cohort Lower GI endoscopy 75 ¢¢ 70 (93%) ¢¢ 13¢0 65¢6 52¢0 + 4¢0 Moderate risk ¢¢
Anand et al., 2017 [48] USA Cohort Lower GI endoscopy 28 28 (100%) 28 (100%) ¢¢ 299¢3 62¢6 78¢5 + NA Moderate risk ¢¢
Hefazi et al., 2017 [49] USA Cohort Lower GI endoscopy 22 ¢¢ 19 (86%) ¢¢ 8¢6 66¢0 57¢0 + 4¢0 Moderate risk ¢¢
Hota et al., 2017 [50] Canada RCT Enema 16 ¢¢ 7 (44%) ¢¢ 17¢0 75¢7 68¢8 + 4¢4 ¢¢ Low risk
Jiang et al., 2017 [51] USA RCT Lower GI endoscopy 72 ¢¢ 63 (88%) ¢¢ 8¢0 67¢0 72¢2 + NA ¢¢ Low risk
Kao et al., 2017 [52] Canada RCT Overall 116 ¢¢ 101 (87%) 105 (91%) 12¢0 58¢0 68¢1 + 4¢0 ¢¢ Low risk
Canada RCT Lower GI endoscopy 59 ¢¢ 50 (85%) 52 (88%) 12¢0 58¢7 75¢4 + 4¢0 ¢¢ Low risk
Canada RCT Capsule 57 ¢¢ 51 (89%) 53 (93%) 12¢0 57¢4 61¢0 + 4¢0 ¢¢ Low risk
Patron et al., 2017 [53] USA Cohort Lower endoscopy 109 ¢¢ 99 (91%) ¢¢ 12¢0 63¢5 64¢2 + 4¢0 Moderate risk ¢¢
van Beurden et al., 2017 [54],e Netherlands Cohort Upper administration 43 ¢¢ 32 (74%) 35 (81%) 8¢0 73¢0 59¢0 + 4¢0 Low risk ¢¢
Staley et al., 2017 [55] USA Cohort Capsule 39 ¢¢ 35 (90%) ¢¢ 8¢0 63¢8 87¢2 + 4¢5 Low risk ¢¢
Jiang et al., 2018 [56] USA RCT Overall 65 ¢¢ 56 (86%) ¢¢ 13¢0 65¢0 70¢8 + 4¢0 ¢¢ High risk
USA RCT Enema 34 ¢¢ 30 (88%) ¢¢ 13¢0 63¢0 74¢0 + 4¢0 ¢¢ High risk
USA RCT Capsule 31 ¢¢ 26 (84%) ¢¢ 13¢0 67¢0 68¢0 + 4¢0 ¢¢ High risk
Allegretti et al., 2018 [57] USA Cohort Lower GI endoscopy 167 160 (96%) 139 (83%) ¢¢ 8¢0 NA NA + NA High risk ¢¢
Duarte-Chavez et al., 2018 [58] USA Cohort Lower GI endoscopy 35 30 (86%) 28 (80%) ¢¢ 13¢0 58¢6 69¢0 + 2¢7 Moderate risk ¢¢
Mihaela et al., 2018 [59] Romania Cohort Lower GI endoscopy 30 28 (93%) 28 (93%) ¢¢ 52¢0 57¢8 46¢7 + 2¢0 Low risk ¢¢
Niccum et al., 2018 [60] USA Cohort Lower GI endoscopy 80 ¢¢ 72 (90%) ¢¢ 13¢0 66¢4 73¢8 + 3¢8 Moderate risk ¢¢
Peri et al., 2019 [61] Germany Cohort Overall 196 ¢¢ 153 (78%) 173 (88%) 12¢9 75¢0 61¢3 + 3¢0 High risk ¢¢
Germany Cohort Upper administration 93 ¢¢ 68 (73%) ¢¢ 12¢9 NA NA + NA High risk ¢¢
Germany Cohort Lower GI endoscopy 73 ¢¢ 63 (86%) ¢¢ 12¢9 NA NA + NA High risk ¢¢
Germany Cohort Capsule 33 ¢¢ 25 (76%) ¢¢ 12¢9 NA NA + NA High risk ¢¢
Germany Cohort Mixed 2 ¢¢ 2 (100%) ¢¢ 12¢9 NA NA + NA High risk ¢¢
Shin et al., 2019 [62] USA Cohort Lower GI endoscopy 44 44 (100%) 42 (95%) ¢¢ 12¢0 67¢0 79¢0 + 3¢0 Moderate risk ¢¢
Lynch et al., 2019 [63] USA Cohort Lower GI endoscopy 92 ¢¢ 79 (86%) ¢¢ 12¢0 64¢8 66¢3 + NA Moderate risk ¢¢
Kim et al., 2019 [64] USA Cohort Overall 35 ¢¢ 30 (86%) ¢¢ 8¢0 NA 85¢7  NA Moderate risk ¢¢
(continued on next page)
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Table 1 (Continued)
FMT Effect Quality assessment
Author Country Study type FMT category Patient
No.
Week 1
Single
Week 8
Single
Week 8
Repeat
Follow-up
(weeks)a
Age
(mean)
Female
(%)
CDAD No. CDI
(mean)
NOS RoB2
Allegretti et al., 2019 [65] USA Cohort Overall 150 ¢¢ 131 (87%) ¢¢ 8¢0 61¢5 68¢7 + 3¢3 Moderate risk ¢¢
USA Cohort Lower GI endoscopy 103 ¢¢ 91 (88%) ¢¢ 8¢0 NA NA + 3¢3 Moderate risk ¢¢
USA Cohort Capsule 47 ¢¢ 40 (85%) ¢¢ 8¢0 NA NA + 3¢3 Moderate risk ¢¢
Hvas et al., 2019 [3] Denmark RCT Overall 24 24 (100%) 22 (92%) 23 (96%) 8¢0 68¢0 69¢0 + 4¢0 ¢¢ Low risk
Denmark RCT Lower GI endoscopy 19 19 (100%) 17 (89%) 18 (95%) 8¢0 NA NA + 4¢0 ¢¢ Low risk
Denmark RCT Upper administration 5 5 (100%) 5 (100%) 5 (100%) 8¢0 NA NA + 4¢0 ¢¢ Low risk
Park et al., 2019 [66] Canada Cohort Lower GI endoscopy 19 ¢¢ 12 (63%) 19 (100%) 8¢0 67¢3 31¢6  NA Moderate risk ¢¢
Allegretti et al., 2019 [67] USA Cohort Capsule 51 ¢¢ ¢¢ 40 (78%) 8¢0 63¢0 68¢0 + 3¢7 Moderate risk ¢¢
Kim et al., 2019 [68] USA Cohort Lower GI endoscopy 105 ¢¢ ¢¢ 91 (87%) 8¢0 66¢0 62¢9 + 3¢3 Low risk ¢¢
Antibiotics
van Nood et al., 2013 [1] Netherlands RCT Vancomycin, standard 26 ¢¢ 7 (27%) 7 (27%) 10¢0 67¢5 38¢5 + 2¢5 ¢¢ Low risk
Cammarota et al., 2015 [2] Italy RCT Vancomycin, pulsed tapered 19 ¢¢ 5 (26%) 5 (26%) 10¢0 75¢0 58¢0 + 3¢0 ¢¢ Low risk
Hota et al., 2017 [50] Canada RCT Vancomycin, tapered 14 ¢¢ 9 (64%) ¢¢ 17¢0 69¢6 66¢7 + 4¢4 ¢¢ Low risk
Hvas et al., 2019 [3] Denmark RCT Vancomycin, standard 16 11 (69%) 5 (31%) 5 (31%) 8¢0 72¢0 69¢0 + 3¢0 ¢¢ Low risk
Hvas et al., 2019 [3] Denmark RCT Fidaxomicin, standard 24 19 (79%) 13 (54%) 13 (54%) 8¢0 64¢0 54¢0 + 4¢0 ¢¢ Low risk
Abbreviations: CDAD: Clostridioides associated diarrhoea, CDI: Clostridioides difficile infection, GI: Gastrointestinal, RCT: Randomised clinical trial, NA: Not available, NOS: Newcastle-Ottawa quality assessment Scale, ROB2: Cochrane
Risk of Bias 2
a Average follow-up time to which the outcome is benchmarked.
b Describes FMT for 20 patients, but for 4 of the patients, demographic data is not reported. 3/4 achieves treatment effect, but is excluded due to lack of data. Data is based on the 16 patients.
c 11 of 49 patients overlap with Mattila 2012, data is based on new patient data from the 38 of 49 patients. Data is available from the publication.
d The extracted data is based on only the donor faeces arm of the RCT.
e Reports data based on 39 patients, but have performed FMT on 43 patients. According to ITT these are included here.
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Table 2
Summary of findings table for faecal microbiota transplantation (FMT) according to delivery method and treatment regimen.
Effect of FMT for recurrent Clostridioides difficile infection grouped by application method and no. of administrations
Patient or population: Patients with recurrent Clostridioides difficile infection Setting: Hospital, outpatient care, home Intervention: Faecal microbiota transplantation (FMT) Comparison: Delivery method and treatment regimen
Comparison: Delivery method (Superiority of one delivery method)
Outcomes Anticipated absolute effect (95% CI) Absolute difference (95% CI) No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
FMT FMT, Lower
GI endoscopy
CDAD week 8, Single FMT:
Overall
Lower GI endoscopy
Upper administration
Capsule
Enema
(Observational studies)
84% (8087%)
90% (8792%)
75% (7080%)
83% (7887%)
57% (4270%)


90%
90%
90%
Not estimable
Not estimable
15 less per 100 (8 to 22 fewer)
7 less per 100 (2 to 12 fewer)
33 less per 100 (15 to 52 fewer)
2743 (41)
1654 (28)
277 (6)a
426 (8)a
397 (5)a
⨁⨁⨁○
MODERATEb,c,d
The quality of the evidence
measures the level certainty
that one method (Lower GI
endoscopy) is superior to
other delivery methods.
CDAD week 8, Repeat FMT:
Overall
Lower GI endoscopy
Upper administration
Capsule
Enema
(Observational studies)
92% (8994%)
95% (9298%)
86% (7892%)
89% (8494%)
88% (8393%)


95%
95%
95%
Not estimable
Not estimable
9 less per 100 (1 to 21 fewer)
6 less per 100 (0 to 15 fewer)
7 less per 100 (2 to 14 fewer)
1513 (22)
725 (12)
114 (5)a
327 (5)a
347 (3)a
⨁⨁⨁□□
LOWb,c
The low quality of evidence
suggests delivery method
following repeat FMT to be
largely equal.
Comparison: Single versus repeat administrations
Outcomes Anticipated effect (95% CI) Absolute difference (95% CI)e No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
FMT, Single FMT, Repeat
CDAD week 8, repeat administrations:
Overall
Lower GI endoscopy
Upper administration
Capsule
Enema
(Observational studies)
79% (7186%)
88% (8392%)
76% (6784%)
81% (7289%)
50% (4555%)
93% (9095%)
96% (9498%)
86% (7892%)
92% (8895%)
88% (8393%)
14 more per 100 (13 to 16 more)
6 more per 100 (7 to 11 more)
10 more per 100 (6 to 17 more)
11 more per 100 (8 to 15 more)
38 more per 100 (33 to 43 more)
1357 (23)
620 (11)
114 (5)
276 (4)
347 (3)
⨁⨁⨁⨁
HIGH c;,d
The quality of the evidence
measures the level of cer-
tainty for the superiority of
repeat FMT.
Abbreviations: CDAD: Clostridioides difficile-associated diarrhoea CI: Confidence intervals, GI: Gastrointestinal
For observational studies the quality of evidence is rated as low per standard.
a Does not include the number of participants in the lower endoscopy group.
b Rated 1 down for risk of bias due to the general lack of comparator a group in each study.
c Rated 1 up for a large magnitude of effect.
d Rated 1 up for a dose-response gradient based on a higher effect following repeat administrations.
e The absolute difference is based on the difference in the weighted average and a generalised Z-statistic for the anticipated difference.
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Table 3
Summary of findings table for faecal microbiota transplantation (FMT) compared with vancomycin.
FMT compared to vancomycin for patients with recurrent Clostridioides difficile infection
Patient or population: Patients with recurrent Clostridioides difficile infection Setting: Hospital, outpatient care, homeIntervention: Faecal microbiota transplantation (FMT)
Comparison: Vancomycin (standard and tapered regimens)
Outcomes Anticipated absolute effect (95% CI)a Difference
(95% CI)
Relative
effect (95% CI)
No. of Participants
(Studies)
Quality of the
evidence (GRADE)
Vancomycin FMT
CDAD week 8, Single FMT:
(Randomised clinical trials)
35% (2546%) 72% (6182%) 35 more per 100 (3 to 67) RR 1.95 (0.93 to 4.0) 151 (4) ⨁⨁⨁○
MODERATEc
CDAD week 8, Repeat FMT:
(Randomised clinical trials)
27% (1840%)b 93% (8497%) 65 more per 100 (52 to 78) RR 3.33 (2.2 to 5.0) 117 (3) ⨁⨁⨁⨁
HIGHd,e
Abbreviations: CDAD: Clostridioides difficile-associated diarrhoea CI: Confidence intervals, RR: Relative Risk.
For randomised clinical trials the quality of evidence is rated as high per standard.
a Anticipated absolute effect is calculated as the crude proportions with corresponding confidence intervals.
b Lower effect in the repeat FMT vancomycin comparator may be due to the exclusion of the group receiving a tapered vancomycin regime in Hota 2017 [50].
c Rated 1 down for imprecision (relative effect CI contains 0) and NOT rated down for inconsistency that may be explained by the use of single FMT enema.
d Rated 1 up for a large magnitude of effect.
e Rated 1 up for a dose-response gradient based on a higher effect following repeat administrations.
Table 4
Estimated effect of fecal microbiota transplantation (FMT) in future
studies stratified according to delivery method.
Intervention Patients no. Estimated
effect rangea
Single FMT, Overall 2754 54100%
Single FMT, Lower GI endoscopy 1654 8196%
Single FMT, Upper administration 277 7080%
Single FMT, Capsule 426 7590%
Single FMT, Enema 397 2684%
Repeat FMT, Overall 1513 8199%
Repeat FMT, Lower GI endoscopy 725 88100%
Repeat FMT, Upper administration 114 7892%
Repeat FMT, Capsule 327 8096%
Repeat FMT, Enema 347 8095%
a Equivalent to the prediction interval.
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8 S.M.D. Baunwall et al. / EClinicalMedicine 00 (2020) 100642significantly increased theoverall treatmenteffectweek8 regardless of
deliverymethod(Fig.2).Thehighestabsoluteincreaseintreatmenteffect
wasobservedforenemaFMTthatincreasedfrom50%(4555%,I2=0%)fol-
lowing single FMT to 88% (8393%, I2 = 37%) for repeat FMT (P<0¢001)
(Table2).Fig. 2. The cumulative effect of faecal microbiota transplantation (FMT) week 8 on recurre
grouped by delivery method. The vertical bars indicate the 95% confidence limits. Abbreviatio
Please cite this article as: S.M.D. Baunwall et al., Faecal microbiota trans
systematic review and meta-analysis, EClinicalMedicine (2020), https://dFMT was compared with antibiotics in four RCTs [1-3,50] with 151
patients (Tables 1 and 3). Repeat FMT was performed in three studies
with 117 patients; and for repeat FMT compared with standard or
tapered vancomycin, repeat FMT had a 65% (5278%, I2=0%, Fig. 3) gain
in absolute treatment effect equivalent to an NNT of 1¢5 (1¢31¢9,
P<0¢001). High quality of evidence supported repeat FMT. For single
FMT versus standard or tapered vancomycin, single FMT had a 35%
(367%, I2=81%, Fig. 3) gain in absolute treatment effect equivalent to
an NNT of 2¢9 (1¢537¢1, P=0¢03). Moderate quality of evidence sup-
ported single FMT. One study with single enema FMT [50] accounted for
all study heterogeneity.
One study [3] compared FMT with fidaxomicin and found a 92%
week 8 effect rate among 24 patients treated with FMT compared
with 42% in 24 patients treated with fidaxomicin.
Publication bias was examined for repeat and single FMT overall
and according to delivery method. For single FMT, the visual inspec-
tion of funnel plots (Supplementary Fig. 4) indicated negative publi-
cation bias that approached statistical significance (Eggert P=0¢057).
Stratifying according to the delivery method (Supplementary Fig. 5)
abrogated this asymmetry, indicating that the asymmetry was intro-
duced by a few, low-effect enema studies relative to the many high-nt Clostridioides difficile infection (CDI) following single and repeated administrations
ns: GI: Gastrointestinal.
plantation for recurrent Clostridioides difficile infection: An updated
oi.org/10.1016/j.eclinm.2020.100642
Fig. 3. Forest plots of the week 8 effects for A) single and B) repeat faecal microbiota transplantation (FMT) versus vancomycin (standard and tapered regimens) on recurrent CDI in
randomised clinical trials.
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repeated FMT (Supplementary Fig. 4), we found no indications of
publication bias (Eggert P=0¢773).
We explored the substantial among study heterogeneity in a
meta-regression including studies reporting effect rates stratified by
delivery method. For repeat FMT, adjusting for the delivery method
reduced the study heterogeneity to minimal (I2=32%). For single FMT,
adjusting for the delivery method and long follow-up times reduced
the study heterogeneity to minimal to moderate (I2=40%). Neither of
the other extracted study parameters, e.g. study type, donor type,
processing methods, nor patient characteristics, including refractory
CDI, listed in Supplementary Tables 2 and 3 influenced study hetero-
geneity.
We did a sensitivity analysis to test the robustness of the findings
and the methodological assumptions. In a series of separate subgroup
analyses, neither high risk of bias, follow-up times above 8 weeks,
nor faecal doses above 50 g significantly changed the estimated effect
rates for repeat or single FMT.4. Discussion
This updated systematic review and meta-analysis demonstrates
a high quality of evidence for the repeated use of FMT in recurrent
CDI and supports that FMT is superior to vancomycin with a number
needed to treat of 1.5 for repeated administrations. The clinical effect
8 weeks after FMT preceded by antibiotics was 91% following repeat
FMT and 84% following a single FMT. Delivery by lower GI endoscopyPlease cite this article as: S.M.D. Baunwall et al., Faecal microbiota trans
systematic review and meta-analysis, EClinicalMedicine (2020), https://dwas superior to all other delivery methods, and the most definite dif-
ference appeared in comparison with delivery by enema.
Previous systematic reviews [1116] demonstrated similar high
effect rates for FMT but did not include both observational and con-
trolled studies. By including both, this review is the first to establish
the quality of evidence for several important clinical determinants
needed to consolidate FMT as an evidence-based treatment. By
updating to the current literature, the sample size almost doubled,
powering this review to evaluate aspects with hitherto less clear
evidence.
The clinical effect of FMT varied according to the delivery
method and the number of administrations. In contrast to previous
reviews [1416], the current review demonstrates that lower GI
endoscopy is superior to all other delivery modalities and not only
enema or upper administration. This underpins lower GI endos-
copy as the gold standard despite the absolute gain of effect rela-
tive to the other delivery methods following repeat FMT is
minimal. When choosing delivery method, the ease of use is an
essential factor, and both capsule and enema FMT have practical
benefits that make FMT easily applicable. Because enema applica-
tion requires repeat administrations for a comparable effect, cap-
sule FMT may eventually prove the better first choice. In this
context, delivery by lower GI endoscopy may be reserved for
patients who fail their initial FMT.
The increase in cumulative FMT effect following repeated admin-
istrations highlights the importance of distinguishing single from
repeat FMT, particularly when evaluating treatment effect. High qual-
ity of evidence applies to repeat FMT only, and studies that solelyplantation for recurrent Clostridioides difficile infection: An updated
oi.org/10.1016/j.eclinm.2020.100642
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rate may further decline with the use of certain delivery methods, e.
g. enema. Thus, Hota et al. [50] demonstrated that a single adminis-
tration of enema FMT was inferior to tapered vancomycin. In future
studies, both treatment regimen and application methods should be
optimised to achieve optimal effect.
The study heterogeneity was substantial and may be due to proce-
dural study differences. In our analysis of study heterogeneity, the
delivery method was the decisive determinant, but we could not
reproduce the previous finding [15,17] that the use of 50 g crude fae-
ces or more was associated with increased treatment success. Nor
did we find that other procedural or methodological factors such as
donor type, fresh, frozen, or lyophilised FMT accounted for study dif-
ferences. These factors may still influence the treatment effect, and
the considerable procedural difference between the studies calls for
studies that evaluate the independent effects of these factors.
The definition of treatment effect differed between the studies.
While most studies reported clinical outcomes according to the
CDAD definition and had a similar long-term follow-up, the short-
term evaluation of the FMT effect varied. In some studies [45], the
treatment effect was evaluated on day 4 while other [44,58] waited
until week 1 after FMT despite ongoing CDAD symptoms. The differ-
ences illustrate the difficulties in keeping a balance between over-
treatment and preventing disease progression. The close-to-
significant effect of FMT at week 1 compared with week 8 indicates
that most patients have an initial treatment response and that most
CDI recurrences happen after week 1. Awaiting week 1 for the treat-
ment effect to settle may thus be suitable if the patients are moni-
tored and the CDI course is not progressive. To harmonise, future
clinical guidelines should make recommendations for the short-term
monitoring and evaluation of patients following FMT.
In all studies, antibiotics treatment of varying duration preceded
FMT, and FMT should be regarded interchangeably as FMT preceded
by antibiotics. The different durations of antibiotics pre-treatment
challenges whether FMT is used prophylactically to prevent further
recurrences or actively to treat an acute CDI. Some patients receive
long-term tapered antibiotics before FMT and have no symptoms at
the time of FMT. In these instances, FMT may be regarded as prophy-
lactic. The distinction may be clinically relevant, but our ability to
evaluate if FMT was applied prophylactically or for the active disease
was limited because no studies made clear distinctions. In the four
RCTs [13,50] with an active antibiotic comparator, FMT was used as
an active treatment for the acute CDI and achieved similar effect rates
to the observational studies that used FMT following prolonged van-
comycin courses.
Despite the vast evidence for the effect of FMT on clinical CDAD
resolution, the evidence levels for FMT to reduce mortality or colec-
tomy rate could not be determined because FMT was offered as a res-
cue treatment in most studies. A few observational studies [69,70]
indicate that FMT reduces the three-month mortality rate, but pro-
viding conclusive evidence may prove difficult because it may be con-
sidered unethical to withhold patients FMT as a rescue treatment
[69]. Acknowledging this limitation may be necessary when evaluat-
ing FMT in future clinical guidelines.
Important limitations apply to this systematic review. We did not
include patients with refractory, index CDI and therefore excluded
high-quality studies reporting combined outcomes; accordingly, the
presented data are only applicable to recurrent CDI. Data to describe
the incremental effect of each repeated administration could not be
extracted. Still, the high effect of repeat FMT suggests that if FMT is
continued until resolution of symptoms occurs, almost all patients
with recurrent CDI eventually achieve treatment effect. Our extrapo-
lation of effect rates reported beyond week 8 may have underesti-
mated the true effect, and it limits the ability to evaluate the effect of
FMT strictly at week 8 according to recommendations for follow-up
[10]. Only few of the included studies performed FMT on patientsPlease cite this article as: S.M.D. Baunwall et al., Faecal microbiota trans
systematic review and meta-analysis, EClinicalMedicine (2020), https://dwith the hypervirulent ribotype 027. Instead to control for the clinical
impact, we used refractory CDI infection as measure for severity of
the infection and found no influence on the clinical effect, but the
clinical effect rates reported in this systematic review may be antici-
pated to differ for patients with the hypervirulent ribotypes.
Future research may determine how FMT performs without anti-
biotic pre-treatment and how it measures in patients with their ini-
tial CDI. Investigations of treatment kinetics, time to effect, required
dosing, and mechanisms of action may guide the clinical use of FMT.
Application of encapsulated donor faeces holds practical benefits but
requires more processing steps that need evaluation in clinical stud-
ies.
In conclusion, high-quality evidence documents FMT as an effec-
tive treatment for recurrent CDI. The effect varies with the delivery
method and the number of administrations, with repeat FMT by
lower GI endoscopy being most effective. The low NNT for FMT ver-
sus antibiotics suggests that advancing the treatment recommenda-
tions for FMT to all instances of recurrent CDI may effectively manage
the infection and provide the most effective patient care.
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